Further evidence that antithrombotic therapy is beneficial with streptokinase: Improved early ST resolution and late patency with enoxaparin

European Heart Journal

Volumn 23, Issue 16, 2002, Pages 1233-1237

  White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; FIBRINOLYTIC AGENT;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG POTENTIATION; EDITORIAL; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; PRIORITY JOURNAL; THROMBOSIS; DRUG COMBINATION; FIBRINOLYTIC THERAPY; METHODOLOGY; NOTE;

DRUG THERAPY, COMBINATION; ENOXAPARIN; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 0036668983     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3246     Document Type: Editorial

References (31)

1. Simoons ML, Krzemiñska-Pakula M, Alonso A et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction; the AMI-SK study. Eur Heart J 2002; 23: 1282-8.
2. Ross AM, Molhoek P, Lundergan C et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-52.
3. Antman EM, Louwerenburg HW, Baars HF et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002; 105: 1642-9.
4. de Lemos JA, Antman EM, Giugliano RP et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am J Cardiol 2000; 85: 299-304.
5. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
6. Kontny F, Dale J, Abildgaard U, PedersenTR, on behalf of the FRAMI Study Group. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997; 30: 962-9.
7. Frostfeldt G, Ahlberg G, Gustafsson G et al. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - A pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33: 627-33.
8. Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study. Clin Cardiol 2001; 24: 1-12-1-14.
9. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) Investigators. Longterm low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study [published erratum appears in Lancet 1999; 354: 1478]. Lancet 1999; 354: 701-7.
10. Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34: 890-911.
11. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992; 101 (4 Suppl): 131S-139S.
12. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336: 847-60.
13. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
14. Hsia J, Hamilton WP, Kleiman N et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-7.
15. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-7.
16. Tardiff BE, McCants B, Hellkamp AS et al. Long term results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial: Sustained benefit of fibrin-specific therapy [abstract]. Circulation 1999; 100 (Suppl 1): I-498-I-499.
17. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction [published erratum appears in N Engl J Med 1994; 330: 516]. N Engl J Med 1993; 329: 1615-22.
18. Antman EM, Giugliano RP, Gibson CM et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-32.
19. White HD. Future of reperfusion therapy for acute myocardial infarction [editorial]. Lancet 1999; 354: 695-7.
20. Van de Werf F, Barron HV, Armstrong PW et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rtPA. Eur Heart J 2001; 22: 2253-61.
21. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-94.
22. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomized trial. Lancet 2001; 357: 1905-14.
23. Hudson MP, Granger CB, Topol EJ et al. Early reinfarction after fibrinolysis: Experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials. Circulation 2001; 104: 1229-35.
24. van Domburg RT, Deckers JW, van Bergen PFMM, Azar AJ, Jonker JJC, Simoons ML. Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction. Netherlands Heart Journal 2001; 9: 166-72.
25. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet 2001; 358: 1855-63.
26. Grines CL, Ellis S, Jones M et al. Primary coronary angioplasty vs. thrombolytic therapy for treatment of acute myocardial infarction (MI). Findings from the PCAT collaboration [abstract]. Eur Heart J 1999; 20 (Abstract Suppl): 170.
27. Andersen HR. The Danish Multicenter Randomized Study on Thrombolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2). Proceedings of the Late Breaking Clinical Trials III Session, 51st American College of Cardiology Annual Scientific Session, Atlanta, Georgia, USA, March 29, 2002.
28. Grines CL, Cox DA, Stone GW et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999; 341: 1949-56.
29. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
30. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
31. Lee Y-K, Nam JH, Shin H-C, Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 2001; 104: 3116-20.